Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.

Participants needed: 387
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: OncoC4, Inc.Updated: Aug 17, 2026Locations: 21
Eligibility criteria

Patient is ≥ 18 years of age on the day of signing informed consent. [+8]

Patients who have not recovered to NCI CTCAE grade ≤ 1 from an adverse event (AE... [+15]

Read more
Status: Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose levels of ONC-841. The Phase 1 part is dose escalation with 7 dose levels of ONC-841 and the dose expansion in the last dose level. The Phase 2 part will test the combination of ONC-841 with SOC in GBM and in CRC.

Participants needed: 72
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: OncoC4, Inc.Updated: Jun 25, 2026Locations: 8
Eligibility criteria

Must have ECOG score ≤ 1. The body weight should be ≥40 kg. [+7]

Patients who have not recovered to NCI CTCAE grade ≤ 1 from an adverse event (AE... [+11]

Read more
Status: Not yet recruiting

Gotistobart Long Term Extension (LTE) Study

This LTE study will examine the long-term overall survival and safety of gotistobart in patients with advanced solid tumors.

Participants needed: 20
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: OncoC4, Inc.Updated: Jun 23, 2026
Eligibility criteria

Age ≥ 18 yrs old patients who provide written informed consent for the study. [+2]

Meet any of the study treatment discontinuation criteria specified in the parent... [+7]

Read more
Status: Not yet recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors

ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer.

Participants needed: 20
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: OncoC4, Inc.Updated: Jun 4, 2026Locations: 2
Eligibility criteria

Age ≥ 18 yrs old. [+8]

Patients who have not recovered to NCI CTCAE Grade ≤ 1 from an adverse event (AE... [+11]

Read more